HLN:NYE-Haleon plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 9.98

Change

-0.01 (-0.10)%

Market Cap

USD 43.18B

Volume

4.58M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.78 (+0.50%)

USD 74.41B
TAK Takeda Pharmaceutical Co Ltd A..

+0.12 (+0.87%)

USD 43.37B
RDY Dr. Reddy’s Laboratories Ltd..

+0.07 (+0.52%)

USD 11.49B
ELAN Elanco Animal Health

-0.11 (-0.98%)

USD 5.69B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.02 (+0.25%)

USD 3.63B
BHC Bausch Health Companies Inc

+0.67 (+10.29%)

USD 2.41B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

+0.01 (+3.14%)

USD 1.96M
EBS Emergent Biosolutions Inc

-0.13 (-1.63%)

N/A
PRGO Perrigo Company PLC

+0.44 (+1.77%)

N/A

ETFs Containing HLN

CUIK:XETRA 4.38 % 0.00 %

N/A

N/A
UKSRE:SW UBS (Irl) ETF plc - MSCI .. 3.41 % 0.00 %

N/A

USD 0.10B
STSX:SW SPDR® MSCI Europe Consum.. 3.33 % 0.00 %

N/A

USD 0.17B
UKSR:SW UBS (Irl) ETF plc - MSCI .. 3.24 % 0.00 %

-0.07 (-0.44%)

USD 0.71B
UKSRT:SW UBS (Irl) ETF plc - MSCI .. 3.24 % 0.00 %

-0.04 (-0.44%)

USD 9.86M
CSPE:LSE SPDR® MSCI Europe Consum.. 2.44 % 0.00 %

-0.45 (-0.44%)

N/A
CSTP:LSE SPDR® MSCI Europe Consum.. 0.00 % 0.00 %

-0.70 (-0.44%)

USD 0.13B
UKSR:LSE UBS (Irl) ETF plc - MSCI .. 0.00 % 0.00 %

-5.40 (-0.44%)

USD 0.72B
XS3R:LSE Xtrackers MSCI Europe Con.. 0.00 % 0.00 %

-7.00 (-0.44%)

USD 0.05B
STS:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.70 (-0.44%)

USD 0.13B
DXSK:F 0.00 % 0.00 %

N/A

N/A
EXV4:F 0.00 % 0.00 %

N/A

N/A
SPYC:F 0.00 % 0.00 %

N/A

N/A
DXSK:XETRA 0.00 % 0.00 %

N/A

N/A
SPYC:XETRA 0.00 % 0.00 %

N/A

N/A
FT1K:LSE Amundi MSCI UK IMI SRI PA.. 0.00 % 0.00 %

-1.20 (-0.44%)

N/A
C1U:PA Amundi FTSE 100 UCITS 0.00 % 0.00 %

-2.20 (-0.44%)

USD 0.04B
ESIH:LSE iShares MSCI Europe Healt.. 0.00 % 0.00 %

N/A

USD 0.81B
ESIS:F 0.00 % 0.00 %

N/A

N/A
ESIS:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.61% 86% B+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.61% 86% B+ 64% D
Trailing 12 Months  
Capital Gain 19.81% 71% C- 75% C
Dividend Return 1.88% 33% F 31% F
Total Return 21.69% 71% C- 74% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.77% 64% D 62% D
Dividend Return 9.34% 57% F 57% F
Total Return 0.57% 33% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.39% 93% A 73% C
Risk Adjusted Return 75.40% 93% A 84% B
Market Capitalization 43.18B 78% C+ 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector